Financial Data and Key Metrics Changes - Revenue for Q2 2025 increased by 26% year over year to $20.2 million, with OviTex revenue growing by 12% and OviTex PRS revenue growing by 53% [28] - Gross margin improved to 69.8% from 68.8% in the prior year, primarily due to lower charges for excess and obsolete inventory [28] - Net loss decreased to $9.9 million from $12.6 million in the prior year [30] Business Line Data and Key Metrics Changes - OviTex unit sales grew by 17% for the quarter, while PRS unit sales grew by 40% [28] - OviTex IHR revenue grew by 322% compared to 2024 and 29% sequentially over Q1 sales [9] - Liquefix revenue saw year-over-year growth of 121% this quarter [8] Market Data and Key Metrics Changes - European sales grew by 25% over Q2 last year, driven by 29% unit growth [10] - Contracts secured with three major national GPOs to improve market access for Liquefix [8] Company Strategy and Development Direction - The company aims to transition from a niche player in complex abdominal wall reconstruction to a broad portfolio provider in hernia repair [60] - A focus on building patient and outcome-centric partnerships with healthcare providers is emphasized [16] - The company is launching educational initiatives targeting teaching hospitals to engage the next generation of surgeons [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of the company and the impact of recent organizational changes on sales performance [33] - The company reiterated its full-year 2025 revenue guidance, anticipating revenue in the range of $85 million to $88 million, representing growth of 23% to 27% over 2024 [30] Other Important Information - The company plans to share a patient case each quarter to highlight the real-world performance of the OviTex platform [31] - Recent publications and presentations have underscored the clinical utility of OviTex products [14] Q&A Session Summary Question: Update on Salesforce headcount and expectations for 2025 - The company has 69 territory managers and 25 account specialists, with plans to reach 76 territory managers [37][39] Question: Update on guidance and revenue cadence - The revenue cadence is expected to follow historical patterns, with a heavier second half compared to the first half [41][42] Question: Details on spending and patient-centric culture - The company is revising travel and expense policies and focusing on recruiting the right hires to enhance patient-centric culture [46][49] Question: Performance of reinforced tissue matrix contracts - Approximately 25 contracts are in place, with positive reception and a focus on patient-centric approaches to transcend existing pricing structures [51][52] Question: Confidence in reiterating sales guidance - Confidence stems from historical performance and the productivity of the sales team, with expectations for increased activity in Q4 [70][72]

Financial Data and Key Metrics Changes - Revenue for the first quarter of 2025 was $18,500,000, representing a 12% increase year-over-year and a 5% sequential growth from the fourth quarter of 2024 [4] - Gross margin decreased to 67.6% from 68.3% in the prior year, primarily due to excess and obsolete inventory adjustments [13] - Net loss for the first quarter was $11,300,000 compared to $5,700,000 in the prior year, largely affected by the previous year's sale of the Nivas product line [15] Business Line Data and Key Metrics Changes - Revenue from OviTex grew 15% year-over-year, while OviTex PRS revenue grew 2% [12] - OviTex unit sales increased by 29% for the quarter, while PRS unit sales declined slightly by 3% [12] - The company reached over 69,000 OviTex hernia implantations since inception, with OviTex IHR and Liquefix each generating over $1,000,000 in sales since their launch in 2024 [9] Market Data and Key Metrics Changes - The European business saw a 17% growth over the first quarter of 2024, indicating strong international demand [5] - The hernia market is shifting away from plastic mesh towards more natural repair products, which positions the company favorably [8] Company Strategy and Development Direction - The company is focused on expanding its commercial organization, with plans to increase the number of territory managers and account specialists [6] - The introduction of larger sizes of OviTex PRS products aims to simplify complex procedures and improve operational efficiency for surgeons [9] - The company is committed to bringing new and complementary products to market, enhancing its product portfolio [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve its 2025 revenue guidance of $85,000,000 to $88,000,000, representing growth of 23% to 27% over 2024 [5][16] - The management highlighted the importance of stability and strength in the sales force, emphasizing a long-term growth strategy rather than short-term gains [25][26] Other Important Information - The company is currently facing a 10% tariff on products shipped from New Zealand, which is expected to negatively impact gross margin by 50 to 100 basis points [11] - The company is working to mitigate tariff impacts by adjusting shipping strategies [11] Q&A Session Summary Question: What are the key factors for continuing sequential growth through the end of the year? - Management noted that historical revenue patterns indicate a larger step up from Q1 to Q2, with continued traction from sales representatives driving growth [21][22] Question: Any changes in competitive hiring dynamics? - Management indicated that the hiring environment has stabilized, with a strong sales force and high morale contributing to retention [27][28] Question: Clarification on tariff impact on gross margin? - Management explained that the tariff impact will gradually affect gross margin starting in Q2, with a projected negative effect of 50 to 100 basis points [38][39] Question: How is the bundling situation with GPOs playing out? - Management emphasized the need to increase the number of surgeons using their products in facilities to justify their market position [45][46] Question: Updated expectations on growth rates for PRS and OviTex? - Management expects continued good growth from both products, with PRS anticipated to grow faster due to its higher average selling price [51][54]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $18.5 million, representing a 12% increase year-over-year and a 5% increase sequentially from Q4 2024 [4][12] - Gross margin decreased to 67.6% from 68.3% in the prior year, primarily due to excess and obsolete inventory adjustments [13] - Net loss for Q1 2025 was $11.3 million compared to $5.7 million in the prior year, largely affected by the previous year's gain from the sale of the Nivas product line [14] Business Line Data and Key Metrics Changes - Revenue from OviTex grew 15% year-over-year, while OviTex PRS revenue grew 2% [12] - Unit sales of OviTex increased by 29% for the quarter, while PRS unit sales declined slightly by 3% [12] - The company has seen strong demand for both OviTex and OviTex PRS, with revenue for each growing approximately 152% [4] Market Data and Key Metrics Changes - The European business experienced a 17% growth over Q1 2024, indicating a strong international opportunity [5] - The hernia market is shifting away from plastic mesh towards more natural repair products, which positions the company favorably [7][29] Company Strategy and Development Direction - The company is reaffirming its 2025 revenue expectation of $85 million to $88 million, representing growth of 23% to 27% over 2024 [5][15] - The new territory manager and account specialist structure is yielding positive results and is expected to enhance sales effectiveness [6] - The company is committed to bringing new and complementary products to market, including larger sizes of OviTex PRS [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercial organization and its ability to drive growth, emphasizing the importance of stability and strength in the sales force [24] - The company is positioned well for continued growth, particularly as the industry moves away from plastic mesh [17] - Management acknowledged the impact of tariffs on gross margin but expects only a modest effect [11][38] Other Important Information - The company has trained 25 new sales team members year-to-date, which is expected to contribute positively to sales [6] - The company is actively working to mitigate the impact of tariffs by adjusting shipping strategies [11] Q&A Session Summary Question: Revenue cadence through the back half of the year - Management noted that historical revenue patterns suggest a larger increase from Q1 to Q2, a smaller increase from Q2 to Q3, and a larger increase from Q3 to Q4 [21][22] Question: Competitive hiring dynamics - Management indicated that the competitive hiring environment has stabilized, with a focus on maintaining morale and a strong sales force [26] Question: Clarification on tariff impact on gross margin - Management explained that the tariff impact would gradually affect gross margin starting in Q2 and continuing into Q3 [37][38] Question: Bundling situation at GPOs - Management emphasized the importance of increasing the number of surgeons using their products in each facility to justify their market position [44][46] Question: Updated expectations on growth rates for PRS and OviTex - Management expects continued good growth from both products, with PRS anticipated to grow faster due to its higher average selling price [50][51]